Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.
Bottom Line: The primary endpoint was safety, focusing on calcium metabolism and hypothalamic-pituitary-adrenal axis function.One patient showed signs of mild adrenal suppression at week 4; the patient discontinued treatment and had normal test results at follow-up 4 weeks later.Mean TSS improved from 6.9 at baseline to 2.9 at treatment end (59% improvement).
Affiliation: Rady Children's Hospital and University of California, San Diego, San Diego, California.Show MeSH
Related in: MedlinePlus
Mentions: Sixteen patients (52%) experienced a total of 20 AEs; 14 were mild in severity and none were serious or lesional/perilesional on the scalp. The most common AEs were cough (n = 3; 10%), oropharyngeal pain (n = 3; 10%), nasopharyngitis (n = 2; 7%), and upper respiratory tract infection (n = 2; 7%). The investigator considered only one AE to be possibly related to study treatment—a patient with laboratory signs of adrenal suppression at week 4 (serum cortisol concentration 16.8 μg/dL at 30 minutes after ACTH challenge; Fig. 2). This adverse drug reaction was judged to be mild. The patient discontinued treatment, and a normal ACTH challenge test was reported at the follow-up visit 4 weeks after the end of study treatment. No other patients showed signs of adrenal suppression.
Affiliation: Rady Children's Hospital and University of California, San Diego, San Diego, California.